SCHEMBL31358742

SCHEMBL31358742

COc1ccc([N+](=O)[O-])cc1-c1ccc(C=C2C(=O)c3ccccc3C2=O)o1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 9/20 0.49
MEN1 O00255 8/20 0.49
POLB P06746 6/20 0.49
TDP1 Q9NUW8 1/20 0.49
XPA P23025 1/20 0.48
MAPT P10636 7/20 0.48
KDM4E B2RXH2 5/20 0.48
L3MBTL1 Q9Y468 4/20 0.48
ALDH1A1 P00352 3/20 0.48
RECQL P46063 3/20 0.48
GLA P06280 2/20 0.48
GAA P10253 2/20 0.48
MCL1 Q07820 2/20 0.48
LMNA P02545 1/20 0.48
THRB P10828 1/20 0.48
CTDSP1 Q9GZU7 2/20 0.47
F5 P12259 1/20 0.47
PPM1G O15355 1/20 0.47
PTPN1 P18031 1/20 0.47
PTPN7 P35236 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31358851 0.91 KMT2A (0.59) KMT2AMEN1POLBTDP1XPA
SCHEMBL31358711 0.85 MAPT (0.64) KMT2AMEN1POLBTDP1MAPT
SCHEMBL31358842 0.84 MEN1 (0.49) KMT2AMEN1POLBTDP1MAPT
SCHEMBL31358883 0.83 GSK3A (0.59) KMT2AMEN1POLBTDP1MAPT
SCHEMBL31358799 0.81 KMT2A (0.66) KMT2AMEN1POLBTDP1MAPT
SCHEMBL31358762 0.81 PIK3CG (0.60) KMT2AMEN1POLBTDP1XPA
SCHEMBL31358774 0.78 BRAF (0.67) KMT2AMEN1POLBTDP1MAPT
SCHEMBL31358739 0.78 MAPT (0.64) KMT2AMEN1POLBTDP1MAPT
SCHEMBL5166948 0.78 MAPT (0.54) KMT2AMEN1POLBTDP1XPA
SCHEMBL5166946 0.78 MAPT (0.54) KMT2AMEN1POLBTDP1XPA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250026741-A1 INHIBITORS OF THE ONCOGENIC SHP2 PHOSPHATASE AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute 2025-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250026741-A1 INHIBITORS OF THE ONCOGENIC SHP2 PHOSPHATASE AND USES THEREOF PTPN18, PTPN7, PTPN1 KMT2A 1043/4885MEN1 2467/4885POLB 3743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.